Table 1.
Demographic and baseline characteristics
| Characteristic | Pexidartinib (N = 40) |
|---|---|
| Median (range) age, years | 40.0 (18–68) |
| Sex, n (%) | |
| Male | 13 (32.5) |
| Female | 27 (67.5) |
| Region, n (%) | |
| Mainland China | 31 (77.5) |
| Taiwan | 9 (22.5) |
| Type of tumor, n (%) | |
| Diffuse | 33 (82.5) |
| Localized | 7 (17.5) |
| Extremity involvement, n (%) | |
| Upper | 5 (12.5) |
| Shoulder | 1 (2.5) |
| Elbow | 3 (7.5) |
| Spine | 1 (2.5) |
| Lower | 35 (87.5) |
| Hip | 8 (20.0) |
| Knee | 18 (45.0) |
| Ankle | 7 (17.5) |
| Foot | 2 (5.0) |
| Prior surgeries for TGCT, n (%) | |
| 0 | 7 (17.5) |
| 1 | 13 (32.5) |
| 2 | 10 (25.0) |
| ≥ 3 | 10 (25.0) |
| Prior systemic therapies, n (%) | |
| None | 36 (90.0) |
| Imatinib | 2 (5.0) |
| Nilotinib | 0 |
| Other | 2 (5.0) |
| Tumor sum of longest diameters, mean (SD), mm | 72.36 (45.55) |
| TVS, mean (SD) | 16.63 (20.70) |
| ROM in affected joints, mean (SD), % relative to reference standard | 67.07 (31.32) |
| PROMIS Physical Function Scale score, mean (SD) | 46.13 (8.58) |
PROMIS, Patient-Reported Outcomes Measurement Information System; ROM, range of motion; SD, standard deviation; TGCT, tenosynovial giant cell tumor; TVS, tumor volume score